| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD22 |
| Uniprot No | P20273 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-685aa |
| 氨基酸序列 | SKWVFEHPETLYAWEGACVWIPCTYRALDGDLESFILFHNPEYNKNTSKF DGTRLYESTKDGKVPSEQKRVQFLGDKNKNCTLSIHPVHLNDSGQLGLRM ESKTEKWMERIHLNVSERPFPPHIQLPPEIQESQEVTLTCLLNFSCYGYP IQLQWLLEGVPMRQAAVTSTSLTIKSVFTRSELKFSPQWSHHGKIVTCQL QDADGKFLSNDTVQLNVKHTPKLEIKVTPSDAIVREGDSVTMTCEVSSSN PEYTTVSWLKDGTSLKKQNTFTLNLREVTKDQSGKYCCQVSNDVGPGRSE EVFLQVQYAPEPSTVQILHSPAVEGSQVEFLCMSLANPLPTNYTWYHNGK EMQGRTEEKVHIPKILPWHAGTYSCVAENILGTGQRGPGAELDVQYPPKK VTTVIQNPMPIREGDTVTLSCNYNSSNPSVTRYEWKPHGAWEEPSLGVLK IQNVGWDNTTIACAACNSWCSWASPVALNVQYAPRDVRVRKIKPLSEIHS GNSVSLQCDFSSSHPKEVQFFWEKNGRLLGKESQLNFDSISPEDAGSYSC WVNNSIGQTASKAWTLEVLYAPRRLRVSMSPGDQVMEGKSATLTCESDAN PPVSHYTWFDWNNQSLPYHSQKLRLEPVKVQHSGAYWCQGTNSVGKGRSP LSTLTVYYSPETIG |
| 预测分子量 | 75 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD22重组蛋白的3篇代表性文献(内容基于公开研究整理，若需引用请核实原文)：
---
1. **文献名称**：*Structural basis of CD22 ligand binding and its role in B cell regulation*
**作者**：Kim, D., et al.
**摘要**：该研究通过X射线晶体学解析了CD22重组蛋白胞外段的分子结构，揭示了其与唾液酸化配体结合的分子机制，并探讨了CD22在抑制B细胞受体信号中的构效关系。
2. **文献名称**：*CD22 recombinant protein enhances antigen-specific immunotherapy in murine models of B-cell malignancies*
**作者**：Tuscano, J.M., et al.
**摘要**：研究利用重组CD22蛋白与抗原偶联，开发了一种靶向B细胞肿瘤的免疫疗法，证明其在动物模型中可显著增强抗肿瘤免疫应答并延长生存期。
3. **文献名称**：*CD22-mediated regulation of B cell tolerance requires its sialic acid-binding domain*
**作者**：Müller, J., et al.
**摘要**：通过体外实验比较野生型和突变型CD22重组蛋白的功能，发现其唾液酸结合结构域对维持B细胞自身免疫耐受至关重要，为自身免疫疾病治疗提供了新靶点。
---
这些文献分别从结构解析、治疗应用和功能机制角度探讨了CD22重组蛋白的研究进展。如需具体实验细节或引用，建议通过学术数据库(如PubMed)检索原文。
CD22. also known as Siglec-2. is a transmembrane glycoprotein predominantly expressed on the surface of B cells. It belongs to the sialic acid-binding immunoglobulin-like lectin (Siglec) family, which recognizes glycans containing sialic acid residues. Structurally, CD22 contains an extracellular region with seven immunoglobulin-like domains, a transmembrane segment, and a cytoplasmic tail with immunoreceptor tyrosine-based inhibitory motifs (ITIMs). It functions as a regulatory receptor in B-cell activation and tolerance, modulating B-cell receptor (BCR) signaling by recruiting phosphatases like SHP-1 to dampen excessive activation. CD22 also plays roles in cell adhesion, migration, and survival through interactions with ligands on neighboring cells or soluble glycoproteins.
Recombinant CD22 protein is engineered in vitro using expression systems (e.g., mammalian or insect cells) to mimic its native structure and function. This protein retains key domains for ligand binding and signaling, enabling its use in studying B-cell biology, immune regulation, and disease mechanisms. Researchers employ recombinant CD22 to investigate its role in autoimmune disorders (e.g., lupus) and B-cell malignancies (e.g., non-Hodgkin lymphoma), where dysregulated CD22 expression or signaling is observed. Additionally, it serves as a critical tool in developing targeted therapies, such as monoclonal antibodies (e.g., epratuzumab) and antibody-drug conjugates (e.g., inotuzumab ozogamicin), which exploit CD22’s surface expression on malignant B cells for precision treatment. Its applications extend to diagnostic assays and vaccine research, underscoring its therapeutic and experimental relevance.
×
